Business Context and Reporting Period
Company: China Pharma Holdings, Inc. (CPHI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Operations: The Company is a Nevada holding company with operations conducted entirely in the People's Republic of China (PRC) through its subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd. It manufactures pharmaceutical products including injectables, tablets, and capsules. The Company is classified as a "smaller reporting company" and a "non-accelerated filer."
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $2,162,054 | $2,294,782 |
| Cost of Revenue | $2,385,125 | $3,600,192 |
| Gross Loss | $(223,071) | $(1,305,410) |
| Operating Loss | $(1,410,738) | $(2,307,573) |
| Net Loss | $(1,313,939) | $(2,394,022) |
| Loss Per Share (Basic/Diluted) | $(0.40) | $(1.63) |
| Cash and Cash Equivalents (End of Period) | $625,032 | $739,337 |
| Net Cash Provided by Operating Activities | $233,258 | $(657,884) |
| Total Assets | $13,766,560 | $14,887,524 |
| Total Liabilities | $7,304,816 | $7,139,620 |
| Stockholders' Equity | $6,461,744 | $7,747,904 |
Debt and Liquidity: As of June 30, 2025, the Company had total lines of credit of approximately $2.02 million ($698k current, $1.32M non-current) and borrowings from related parties of $1.41 million. Current liabilities ($5.25M) exceeded current assets ($2.70M) by $2.55 million.
Material Changes vs. Prior Period
- Revenue: Decreased 5.8% to $2.16 million for the six months ended June 30, 2025, compared to $2.29 million in the prior year. The decline was driven by a 11% drop in the "Anti-Viral/Infection & Respiratory" category, partially offset by growth in "CNS Cerebral & Cardio Vascular" (up 7%) and "Digestive Diseases" (up 38%).
- Profitability: Net loss improved significantly, decreasing 45% to $1.31 million from $2.39 million. Gross loss narrowed from $1.31 million to $0.22 million, primarily due to reduced amortization of property, plant, and equipment (PP&E) and lower inventory obsolescence allowances.
- Expenses: General and administrative (G&A) expenses increased 63% to $0.95 million, driven by higher amortization of intangible assets. Conversely, R&D expenses decreased 74% to $0.05 million due to a refund received from a defaulted outsourced project partner.
- Cash Flow: Operating cash flow turned positive, providing $0.23 million compared to a usage of $0.66 million in the prior year, aided by improvements in working capital management.
Outlook, Risks, and Management Commentary
- Going Concern: Management has disclosed substantial doubt about the Company's ability to continue as a going concern within one year. This is due to an accumulated deficit of $45.3 million, recurring net losses, and a working capital deficit. The Company relies on advances from its Chairperson/CEO (totaling $1.41 million as of June 30, 2025) and existing lines of credit to fund operations.
- Strategic Initiatives: Management plans to enhance sales models (advance payments), strengthen accounts receivable collection, and explore strategic alternatives for nutrition products. Cost reduction measures include consolidating procurement, optimizing production cycles, and reducing marketing spend to high-return channels.
- Regulatory Environment: The Company faces challenges from China's Centralized Procurement (CP) policies, which significantly reduce drug prices. Progress on generic drug consistency evaluations has been slow due to changing policies and ROI considerations.
- Internal Controls: The Company identified a material weakness in internal controls over financial reporting due to a lack of personnel knowledgeable in U.S. GAAP. Disclosure controls were deemed ineffective as of June 30, 2025.
- Stock Split: A 1-for-10 reverse stock split was implemented on April 15, 2025. All share and per-share data in the filing have been retroactively restated.
Investor Verification Checklist
- Going Concern Status: Verify the sustainability of operations given the $2.55 million working capital deficit and reliance on related-party funding.
- Accounts Receivable Quality: Note that 98% of gross trade receivables are aged over 720 days, with an allowance for credit losses of $13.64 million (98.1% of gross receivables).
- Revenue Concentration: Confirm exposure to key customers; two customers accounted for 77.2% of accounts receivable, and three products accounted for 69.1% of revenue.
- Related Party Transactions: Review the $1.41 million owed to the Chairperson/CEO and the $1.60 million in compensation payable to officers.
- Internal Control Weaknesses: Assess the risk of financial misstatement given the admitted lack of U.S. GAAP expertise and ineffective disclosure controls.